Comment

. 2018 Feb;19(2):e69.

doi: 10.1016/S1470-2045(18)30025-1.

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Josep M Llovet¹, Richard S Finn²

Affiliations

¹ Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Barcelona-Clínic Liver Cancer Group (BCLC), Unitat d'Hepatologia, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address: jmllovet@clinic.cat.
² Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

PMID: 29413470
DOI: 10.1016/S1470-2045(18)30025-1

Comment

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Josep M Llovet et al. Lancet Oncol. 2018 Feb.

. 2018 Feb;19(2):e69.

doi: 10.1016/S1470-2045(18)30025-1.

Authors

Josep M Llovet¹, Richard S Finn²

Affiliations

¹ Mount Sinai Liver Cancer Program, Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Barcelona-Clínic Liver Cancer Group (BCLC), Unitat d'Hepatologia, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. Electronic address: jmllovet@clinic.cat.
² Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

PMID: 29413470
DOI: 10.1016/S1470-2045(18)30025-1

No abstract available

PubMed Disclaimer

Comment in

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC - Authors' reply.
Vilgrain V, Pereira H, Dinut A, Chatellier G. Vilgrain V, et al. Lancet Oncol. 2018 Feb;19(2):e71. doi: 10.1016/S1470-2045(18)30031-7. Lancet Oncol. 2018. PMID: 29413472 No abstract available.

Comment on

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Vilgrain V, et al. Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26. Lancet Oncol. 2017. PMID: 29107679 Clinical Trial.

Cited by

Improved Survival after Transarterial Radioembolisation for Hepatocellular Carcinoma Gives the Procedure Added Value.
Mosconi C, Cappelli A, Pettinato C, Cocozza MA, Vara G, Terzi E, Morelli MC, Lodi Rizzini E, Renzulli M, Modestino F, Serenari M, Bonfiglioli R, Calderoni L, Tabacchi E, Cescon M, Morganti AG, Trevisani F, Piscaglia F, Fanti S, Strigari L, Cucchetti A, Golfieri R. Mosconi C, et al. J Clin Med. 2022 Dec 16;11(24):7469. doi: 10.3390/jcm11247469. J Clin Med. 2022. PMID: 36556085 Free PMC article.
Standard Radiation Dosimetry Models: What Interventional Radiologists Need to Know.
Webster LA, Villalobos A, Majdalany BS, Bercu ZL, Gandhi RT, Kokabi N. Webster LA, et al. Semin Intervent Radiol. 2021 Oct;38(4):405-411. doi: 10.1055/s-0041-1732323. Epub 2021 Oct 7. Semin Intervent Radiol. 2021. PMID: 34629706 Free PMC article. Review.
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Llovet JM, et al. Nat Rev Gastroenterol Hepatol. 2021 May;18(5):293-313. doi: 10.1038/s41575-020-00395-0. Epub 2021 Jan 28. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33510460 Review.
Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Walton M, et al. Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480. Health Technol Assess. 2020. PMID: 33001024 Free PMC article.
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update.
Kishore SA, Bajwa R, Madoff DC. Kishore SA, et al. Cancers (Basel). 2020 Mar 26;12(4):791. doi: 10.3390/cancers12040791. Cancers (Basel). 2020. PMID: 32224882 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Affiliations

Negative phase 3 study of ⁹⁰Y microspheres versus sorafenib in HCC

Authors

Affiliations

Comment in

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Comment in

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical